's () Tim Mitchell caught up with Proactive London's Andrew Scott following the news it's raised just over £1mln to advance the preclinincal work on its TYK2/JAK1 drugs SDC-1801 and SDC-1802.
Mitchell says they're exploring the potential benefit of the TYK2/JAK1 inhibitors against coronavirus (COVID-19) as well as in cancer and autoimmune diseases.
Preparatory work is being made to advance candidates towards human trials.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Sareum Holdings PLC named herein, including the promotion by the Company of Sareum Holdings PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE